Optical probe for in situ assessment of pulmonary fibrosis

用于肺纤维化原位评估的光学探头

• 批准号: 9907714
• 负责人: NICUSOR IFTIMIA
• 金额: $ 23万
• 依托单位: PHYSICAL SCIENCES, INC
• 依托单位国家: 美国
• 财政年份: 2020
• 资助国家: 美国
• 起止时间: 2020-02-01 至 2022-07-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9907714
• 关键词: Air Sacs; Animal Model; Animals; Biopsy; Birefringence; Bleomycin; Blood; Blood Circulation; Breathing; Bronchioles; Caliber; Chest wall structure; Chronic; Cicatrix; Clinical; Collaborations; Complex; Connective Tissue; Critical Care; Data; Development; Diagnosis; Diagnostic; Disease; Emotional; Evaluation; Excision; Exposure to; Fibrosis; General Anesthesia; General Hospitals; Goals; Government; Health; Health Care Costs; Healthcare; Hemorrhage; Histology; Human; Image; Imaging technology; In Situ; Inflammation; Israel; Laboratories; Lateral; Letters; Lung; Lung diseases; Massachusetts; Measures; Medicine; Microanatomy; Microscopy; Modeling; Morbidity - disease rate; Morphology; Needles; Office Visits; Optical Biopsy; Optical Coherence Tomography; Optics; Oxygen; Pathologic; Pathology; Patients; Pattern; Persons; Phase; Pilot Projects; Procedures; Process; Pulmonary Fibrosis; Quality of life; Radiologic Finding; Radiology Specialty; Rattus; Research; Resolution; Resources; Roentgen Rays; Safety; Scientist; Sensitivity and Specificity; Services; Shortness of Breath; Sterilization; Stethoscopes; Structure; Technology; Testing; Tissues; Tube; United States; X-Ray Computed Tomography; accurate diagnosis; base; clinical research site; cost; experience; experimental study; human model; idiopathic pulmonary fibrosis; imaging probe; improved; in vivo; in vivo evaluation; instrument; lung imaging; mechanical properties; minimally invasive; multidisciplinary; new technology; novel; optical imaging; physical science; pre-clinical; procedure cost; programs; rapid diagnosis; side effect; success; technology development; tissue processing

Project Summary/Abstract Physical Sciences Inc. (PSI), in collaboration with the Department of Pathology at the Massachusetts General Hospital (MGH) and the Divisions of Pulmonary and Critical Care Medicine at MGH and Beth Israel Lahey Health (BILH), proposes to develop and evaluate a novel technology for assessing pulmonary fibrosis, which is a respiratory disease leading to serious breathing problems. This disease consists of the accumulation of excess fibrous connective tissue within the lungs (this process is called fibrosis), leading to thickening of the walls of the bronchioles, and thus causes reduced oxygen supply in the blood. As a consequence patients suffer from perpetual shortness of breath. Pulmonary fibrosis is usually diagnosed during regular doctor office visits, by listening with the stethoscope, and confirmed with X-rays and CT scanning. However, since misdiagnosis is common, biopsy is ultimately performed to confirm findings. Unfortunately, large pieces of tissue are needed to evaluate the presence of fibrosis. Therefore, video assisted thoracoscopic wedge biopsy (VATS) is used for this purpose. This procedure has multiple side effects, including inflammation, tissue morbidity, and severe bleeding. Furthermore, since it requires tissue processing and pathologic interpretation, the procedure becomes expensive, while the results are not immediately available. PSI's proposed alternative approach to regular VATS wedge resections is to investigate tissue morphology and mechanical properties in situ by using a minimally invasive needle-type smart optical probe, which eliminates the need to remove any tissue. Furthermore, the results are immediately available during biopsy. This technology will be first tested In Phase I in a Bleomycin-induced pulmonary fibrosis rat model to determine its efficacy for reliable diagnosis. Based on Phase I findings, the technology will be further improved during Phase II and its efficacy will be further tested in human patients at MGH and BILH. Successful development and demonstration of the proposed PSI technology will enable reliable improved diagnosis at lower costs while eliminating side effects associated to the regular biopsy.

项目概要/摘要 物理科学公司 (PSI) 与马萨诸塞州病理学系合作 总医院 (MGH) 以及 MGH 和 Beth Israel 的肺科和重症监护医学科 Lahey Health (BILH) 提议开发和评估一种评估肺纤维化的新技术， 这是一种导致严重呼吸问题的呼吸系统疾病。这种疾病的特点是积聚 肺内多余的纤维结缔组织（此过程称为纤维化），导致肺膜增厚 细支气管壁，从而导致血液中的氧气供应减少。结果患者 患有永久性呼吸短促。肺纤维化通常是在正规医生办公室诊断出来的 通过听诊器听诊，并通过 X 射线和 CT 扫描确认。然而，自从 误诊很常见，最终进行活检以确认结果。不幸的是，大块 需要组织来评估纤维化的存在。因此，视频辅助胸腔镜楔形活检 （VATS）就是用于此目的。该手术有多种副作用，包括炎症、组织 发病率和严重出血。此外，由于它需要组织处理和病理解释， 该过程变得昂贵，而且结果不能立即获得。 PSI 提出的常规 VATS 楔形切除术的替代方法是研究组织形态 通过使用微创针型智能光学探头进行原位机械性能测量， 无需去除任何组织。此外，在活检过程中可以立即获得结果。 该技术将首先在第一阶段进行测试 博莱霉素诱导的肺纤维化 大鼠模型测定 其对于可靠诊断的功效。基于第一阶段的研究结果，该技术将在 II 期临床试验及其疗效将在 MGH 和 BILH 的人类患者身上进行进一步测试。开发成功 拟议的 PSI 技术的演示将以较低的成本实现可靠的改进诊断，同时 消除与定期活检相关的副作用。